These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 21459935)

  • 1. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
    Ruff CT; Morrow DA; Jarolim P; Ren F; Contant CF; Kaur A; Curtis SP; Laine L; Cannon CP; Brune K
    J Rheumatol; 2011 Jun; 38(6):1071-8. PubMed ID: 21459935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial.
    Brune K; Katus HA; Moecks J; Spanuth E; Jaffe AS; Giannitsis E
    Clin Chem; 2008 Jul; 54(7):1149-57. PubMed ID: 18451314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
    Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P
    JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure.
    Skoglund PH; Arpegård J; Ostergren J; Svensson P
    Am J Hypertens; 2014 Mar; 27(3):363-71. PubMed ID: 24470529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
    Bibbins-Domingo K; Gupta R; Na B; Wu AH; Schiller NB; Whooley MA
    JAMA; 2007 Jan; 297(2):169-76. PubMed ID: 17213400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP; Curtis SP; Bolognese JA; Laine L;
    Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
    Huang PH; Lu TM; Wu TC; Lin FY; Chen YH; Chen JW; Lin SJ
    Coron Artery Dis; 2008 May; 19(3):187-93. PubMed ID: 18418236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors.
    Avouac J; Meune C; Chenevier-Gobeaux C; Dieudé P; Borderie D; Lefevre G; Kahan A; Allanore Y
    J Rheumatol; 2014 Feb; 41(2):248-55. PubMed ID: 24334650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    J Hypertens; 2008 Jan; 26(1):26-34. PubMed ID: 18090537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old markers, new approach to assessment of risk in heart failure.
    Kodziszewska K; Leszek P; Korewicki J; Piotrowski W
    Kardiol Pol; 2015; 73(6):387-95. PubMed ID: 25563469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?
    Ezekowitz JA; Théroux P; Welsh R; Bata I; Webb J; Armstrong PW
    Can J Physiol Pharmacol; 2007 Jan; 85(1):173-8. PubMed ID: 17487257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    Eur Heart J; 2007 Jun; 28(11):1374-81. PubMed ID: 17242007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery.
    Schouten O; Hoeks SE; Goei D; Bax JJ; Verhagen HJ; Poldermans D
    J Vasc Surg; 2009 Feb; 49(2):435-41; discussion 441-2. PubMed ID: 19028043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
    Tang WH; Steinhubl SR; Van Lente F; Brennan D; McErlean E; Maroo A; Francis GS; Topol EJ
    Am Heart J; 2007 Jan; 153(1):36-41. PubMed ID: 17174634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.